Skip to main content
Log in

Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon α in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment

  • Original Papers
  • Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

We describe here a mainly topical interleukin-2 (IL-2) application in pulmonary metastatic renal-cell carcinoma: a high-dose long-term inhalation of IL-2 (90% of IL-2 dose) and low-dose systemic subcutaneous IL-2 (10% of IL-2 dose) and systemic subcutaneous interferon α (IFN α). The effectiveness of this treatment is remarkable. No pulmonary metastases progressed during treatment. One complete response, 8 partial responses, and 6 cases of stable disease were achieved in the lungs of the 15 patients. In addition, 3 of 7 patients had partial responses and 1 of 7 had stabilization of non-pulmonary metastases. Overall response according to WHO criteria was 1 complete response, 6 partial responses, 2 mixed responses, 5 stable diseases and 1 progressive disease. Toxicity was low. Only WHO grade I toxicity occurred, except for a single grade II event (bronchospasm). This allowed long-term ambulatory treatment (1–23 months) inclusion of high-risk patients, and inclusion of patients with advanced disease. The expected mean survival of patients was 9.9 months, the actual mean survival is now 19.1 months, and 11 of 15 patients are still alive. Quality of life during treatment was good. Inhalation of IL-2 serves as a clinical model for high effectiveness and low toxicity of long-term local IL-2 application. We conclude that mainly local treatment might be the key to successful nontoxic use of IL-2 in cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abrams J, Rayner A, Wiernik A, Parkinson D et al. (1989) High dose interleukin-2 without lymphokine activated killer cells. Inactive in advanced renal-cell cancer. Proc Am Assoc Cancer Res 30:A1507

    Google Scholar 

  • Atzpodien J, Körfer A, Franks CR, Poliwoda H et al. (1990) Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies. Lancet 335:1509

    PubMed  Google Scholar 

  • Aulitzky WE, Kessler M, Wilhelm M, Huland E et al. (1993) Aerosolized natural interleukin 2 for treatment of advanced malignancy: results of a phase I trial. Ann Hematol 66 [Suppl 2]:A109

    Google Scholar 

  • Bartsch HH, Adler M, Ringert RH et al. (1990) Sequential therapy of recombinant interferon alpha (IFN-A) and recombinant interleukin-2 (IL-2) in patients with advanced renal-cell carcinoma (RCC). Proc Annu Meet Am Soc Clin Oncol 9:A556

    Google Scholar 

  • Bubenik J, Perlmann P, Indrova M et al. (1983) Growth inhibition of an MC induced mouse sarcoma by TCGF (IL-2)-containing preparations. Cancer Immunol Immunother 14:205–206

    PubMed  Google Scholar 

  • Bukowski RM, Goodman P, Crawford ED et al. (1989) Phase II evaluation of recombinant interleukin-2 (RIL-2) in metastatic renal-cell carcinoma (RCC): SWOG 8617. Proc Annu Meet Am Soc Clin Oncol 8:A556

    Google Scholar 

  • Elson PJ, Witte RS, Trump DL (1988) Prognostic factors for survival in patients with recurrent or metastatic renal-cell carcinoma. Cancer Res 48:7310–7313

    PubMed  Google Scholar 

  • Ettinghausen SE, Rosenberg SA (1986) Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res 46:1784–1792

    Google Scholar 

  • Figlin R, Citron M, Whitehead R et al. (1990) Low dose continuous infusion recombinant human interleukin-2 (rhIL-2) and roferon; an active outpatient regimen for metastatic renal-cell carcinoma (RCCa). Proc Annu Meet Am Soc Clin Oncol 9:A553

    Google Scholar 

  • Gering AJH, Thorpe R (1988) Immunological standardization. The international standard for human interleukin-2. Calibration by international collaborative study. J Immunol 114:3–9

    Google Scholar 

  • Grimm EA, Mazumder A, Zhang HZ et al. (1982) Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous peripheral blood lymphocytes. J Exp Med 155:1823–1841

    PubMed  Google Scholar 

  • Heinzer H, Huland E, Huland H (1992) Adverse reaction to contrast material in a patient treated with local interleukin-2. Am J Radiol 158:1407

    Google Scholar 

  • Huland E, Huland H (1989) Local continuous high dose interleukin-2. A new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 49:5469–5474

    PubMed  Google Scholar 

  • Huland E, Huland H, Heinzer H (1992) Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma. J Urol 147:344–348

    PubMed  Google Scholar 

  • Lafreniere R, Rosenberg SA (1985 a) Successful immunotherapy of murine experimental hepaptic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 45:3735–3741

    PubMed  Google Scholar 

  • Lafreniere R, Rosenberg SA (1985 b) Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol 135:4273–4280

    PubMed  Google Scholar 

  • Lindemann A, Monson JRT, Stahel RA et al. (1990) “Low-intensity” combination treatment with r-interleukin-2 (rh-IL-2) and r-interferon alfa-2a (rh-IFN-a-2a) in renal-cell carcinoma. A multicenter phase II trial. Proc Annu Meet Am Soc Clin Oncol 9:A584

    Google Scholar 

  • Markowitz A, Talpaz M, Lee K et al. (1989) Phase I–II study of recombinant interleukin-2 (RIL-2) plus recombinant interferon-alpha 2a (FIFN-alpha) in renal-cell carcinoma (RCC). Proc Annu Meet Am Soc Clin Oncol 8:A568

    Google Scholar 

  • Mittelman C, Puccio C, Ahmed T et al. (1990) Phase II trial of recombinant interleukin-2 (IL-2) and roferon A (IFN) in patients (PTS) with advanced renal-cell carcinoma. Proc Annu Meet Am Soc Clin Oncol 9:A736

    Google Scholar 

  • Philip T, Stoter G, Jasmin C et al. (1989) Recombinant human interleukin-2 with or without LAK cells in metastatic renal-cell carcinoma. Proc Annu Meet Am Soc Clin Oncol 8:A507

    Google Scholar 

  • Rosenberg SA, Lotze MT, Leitman S et al. (1985 a) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492

    PubMed  Google Scholar 

  • Rosenberg SA, Mulé JJ, Spiess PJ et al. (1985 b) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161:1169–1188

    PubMed  Google Scholar 

  • Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318–1321

    PubMed  Google Scholar 

  • Rosenberg SA, Lotze MT, Muul LM et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897

    PubMed  Google Scholar 

  • Rossio JL, Thurman GB, Long C et al. (1989) The BRMP IL-2 reference reagent. Lymphokine Res 5 [Suppl 1]:13

    Google Scholar 

  • Sosman JA, Kohler PC, Hank J et al. (1988 a) Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 80:60

    PubMed  Google Scholar 

  • Sosman JA, Kohler PC, Hank J et al. (1988 b) Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst 80:1451

    PubMed  Google Scholar 

  • Voss SD, Weil-Hillman G, Hank JA et al. (1989) The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment. Bull NY Acad Med 65:93–110

    Google Scholar 

  • Wang J, Walle A, Gordon B et al. (1987) Adoptive immunotherapy for stage IV renal-cell carcinoma. A novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2. Am J Med 83:1016–1023

    PubMed  Google Scholar 

  • West WH, Tauer KW, Yannli JR et al. (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898–905

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huland, E., Heinzer, H. & Huland, H. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon α in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment. J Cancer Res Clin Oncol 120, 221–228 (1994). https://doi.org/10.1007/BF01372560

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01372560

Key words

Navigation